Objective. RhD-positive subjects are protected against toxoplasmosis-associated impairment of psychomotor performance. Here we searched for RhD-positivity-associated maternal protection against the effects of toxoplasmosis. Methods. In the present retrospective cohort study, we analysed data from 785 (139 RhD-negative) Toxoplasma-free and 194 (27 RhD-negative) Toxoplasma-infected pregnant women. We searched for effects of toxoplasmosis and Rhdphenotype on maternal weight before pregnancy, pregnancy weight gain, fetal ultrasound data (biparietal diameter, abdominal circumference, femur length) and on birth length and weight. Results. At pregnancy week 16, the RhD-negative mothers with toxoplasmosis gained more weight than others (P < 0·001). The difference of about 1600 g remained approximately constant from pregnancy week 16 until the end of pregnancy. Neither toxoplasmosis nor RhD phenotype had any effect on fetal bioparameter data or birth length and weight. Conclusion. The most parsimonious explanation for the observed data is that the RhD-positive phenotype might protect infected subjects against a broad spectrum of detrimental effects of latent toxoplasmosis, including excessive gestational weight gain.
I N T R O D U C T I O N
Toxoplasmosis, a zoonosis caused by the protozoan, Toxoplasma gondii, is probably the most widespread human parasitosis in developed countries. In immunocompetent humans, post-natally acquired toxoplasmosis is either inapparent or is accompanied by cervical lymphadenopathy with fever, joint pain, headache and tiredness (Jones et al. 2001) . The acute disease promoted by rapidly dividing tachyzoites usually spontaneously proceeds to the latent toxoplasmosis. During latent toxoplasmosis, the parasite survives in the form of bradyzoites in tissue cysts, usually providing immunity against re-infection for the rest of the host's life. Latent toxoplasmosis is generally considered to be clinically asymptomatic; however, it is accompanied by specific changes in the personality profile, behaviour and psychomotor performance (Havlíček et al. 2001; Flegr et al. 1996; Lindová et al. 2006) . The most damaging form of toxoplasmosis is congenital toxoplasmosis. In pregnant women with the acute form of infection, the parasite can infect the placenta and, after a lag period, also the fetus. Approximately 20% of infants with congenital infection have severe disease. Approximately 70% are asymptomatic at birth but can later develop clinical signs, i.e. slower neurological and mental development and late chorioretinitis (Tenter et al. 2000) .
For neonates born to mothers with latent toxoplasmosis, neither pathological changes nor health damage due to maternal toxoplasmosis have been reported. Possible effects of latent toxoplasmosis on the risk of abortion were speculated (Kimball et al. 1971) ; however, this speculation has not been confirmed in later studies (Giorgino and Maga, 1981; Quablan et al. 2002) . Pregnant women with latent toxoplasmosis have been reported to have seemingly younger (less developed) fetuses at pregnancy week 16 and longer pregnancy (Flegr et al. 2005; Kaňková and Flegr, 2007) . Several explanations for this finding were suggested, including retarded fetal growth in Toxoplasma-infected women.
Recently, a protective effect of RhD positivity against latent toxoplasmosis-associated impairment of psychomotor performance has been observed in 3 independent sets of male blood donors, 1 set of male conscripts (Novotná et al. 2008) , 1 set of female students (Flegr et al. 2008a ) and 1 set of military drivers (Flegr et al. 2009 ). The first 2 studies have shown that RhD-positive subjects, especially the heterozygotes, are protected against toxoplasmosisassociated prolongation of reaction times and the third study has shown that RhD-positive drivers are protected against toxoplasmosis-associated increase of risk of traffic accident. The RhD protein, a product of the RHD gene, is a major component of the Rh blood group system and carries the strongest blood group immunogen, the D antigen. The structure homology data suggest that the RhD protein acts as an ion pump of uncertain specificity and unknown physiological role. This antigen is absent in a significant minority of the human population (RhD negatives) due to the RHD deletion.
Until now, only the protective effects of RhD-positivity against psychomotor deterioration (Novotná et al. 2008; Flegr et al. 2008a , and personality changes and ageing ) have been studied. It is not known whether RhDpositive subjects are also protected against other effects of toxoplasmosis on human behaviour (Lindová et al. 2006 (Lindová et al. , 2010 , level of testosterone (Flegr et al. 2008b) , sex ratio (Kaňková et al. 2007a, b) and embryonic development (Flegr et al. 2005; Kaňková and Flegr, 2007) or length of pregnancy (Kaňková and Flegr, 2007) . In the present study, we searched for differences in the response of RhD-positive and RhD-negative mothers to latent Toxoplasma infection, namely a maternal weight before pregnancy, an increase of pregnancy weight gain, fetal bioparameters, birth length and birth weight of newborns, by analysing clinical records of 1053 pregnancies.
M A T E R I A L S A N D M E T H O D S

Subjects
The experimental set consisted of clients of 2 clinics (Reproductive Medicine Centres in Prague 5 and Prague 8). The experimental design was a cohort study. With the help of the personnel from these clinics, anonymous data were collected on the progress of 1053 pregnancies. The original data set included records of all clients tested for toxoplasmosis from 1996-2004 who were Czech citizens and resided in Prague. Women were tested for toxoplasmosis at about pregnancy week 16. The presence of antibodies against Toxoplasma was diagnosed with the indirect immunofluorescence test at dilutions between 1:8 and 1:1024. The samples with specific fluorescence visible at a 1:16 or higher dilution were considered as Toxoplasma-infected. Clinical records comprised maternal anti-Toxoplasma antibody titres, maternal age, number of previous deliveries, number of previous abortions, maternal weight before the pregnancy and at pregnancy weeks 16, 20, 30 and about 36, Rh factor, newborn's sex and birth weight and length, date of the last menstrual period, pregnancy length estimated based on the first ultrasound (mostly between pregnancy weeks 8 and 12), and fetal ultrasound data (biparietal diameter, abdominal circumference, femur length) obtained approximately at pregnancy weeks 20 and 30.
The study was approved by the Institutional Review Board of the Charles University, Faculty of Sciences and complied with the current laws of the Czech Republic.
Statistical analysis
The SPSS 16.0 was used for all statistical testing including General Linear Model (GLM) tests (the more robust analogy of ANOVA and ANCOVA test) and testing of statistical assumptions (normality of data and normality of residuals using Shapiro-Wilks tests and residual graphs, homogeneity of variances using Levene's test for homogeneity of variances). The significance was shown as two-tailed p and strength of effects was shown as two-tailed p and η 2 (analogy of R 2 of ANOVA, reflecting part of total variability of a dependent variable that can be explained by a particular factor). Maternal weight before pregnancy had a non-normal distribution, and therefore we log-transformed the data prior to analysis. Other statistical tests were performed with raw, non-transformed data; however, there was practically no difference between the results obtained with and without log transformation of the maternal weight gain data.
R E S U L T S
The mean maternal age was 30 years (range 19-44 years). The data set included 642, 342, 58, 10 and 1 records of the first, second, third, fourth and fifth pregnancy, respectively. Thirty-six women gave birth to twins whose data were excluded from the data set. Women with incomplete clinical records (e.g. without results of some clinical tests) were excluded from particular statistical tests. Our final set consisted of 979 mothers. Among 785 (80·2%) Toxoplasma-free mothers, 139 (17·7%) were RhD negative and among 194 (19·2%) Toxoplasmainfected mothers, 27 (13·9%) were RhD negative. The mean maternal weight before pregnancy was 61·86 kg and mean maternal weight gains were 2·63 kg, 4·66 kg, 9·92 kg, and 13·73 kg at pregnancy weeks 16, 20, 30 and 36, respectively. We analysed the influence of toxoplasmosis and RhD on maternal weight before pregnancy. Toxoplasma-infected mothers had higher mean weight than Toxoplasma-free mothers (63·56 kg and 61·48 kg, respectively). The difference was significant in a simple general linear model with toxoplasmosis (toxo) and maternal age as independent variables (P = 0·023, η 2 = 0·005); however, the analysis with RhD, toxo and maternal age as independent variables showed no effect of toxo (P = 0·114, η 2 = 0·002). Similarly, the effect of neither RhD (P = 0·313, η 2 = 0·001) nor toxo-RhD interaction (P = 0·886, η 2 < 0·001) on maternal weight before pregnancy was significant (Fig. 1) . The continuous predictor maternal age has significantly positive influence on maternal age both in the model with the RhD variable (P = 0·001, η 2 = 0·011) and the simple model without the RhD variable (P = 0·001, η 2 = 0·011). The influence of toxo-RhD interaction on maternal weight gain at pregnancy weeks approximately 16, 20 and 30 was evaluated by the GLM in sets of 900, 933 and 936 mothers, respectively. The models contained the independent binary variables toxo, sex of newborn child and RhD and continuous variables maternal age, maternal weight before pregnancy and presumptive pregnancy length (age of the fetus in days). The sex of the newborn child and maternal weight before pregnancy had no effect on maternal weight gain and therefore, these factors were excluded from final testing. The effect of toxo was significant in pregnancy weeks 16 (P = 0·006, η 2 = 0·009) and 20 (P = 0·049, η 2 = 0·004) and nearly significant in pregnancy week 30 (P = 0·073, η 2 = 0·003). The effect of RhD was significant in pregnancy week 16 (P = 0·001, η 2 = 0·012) but was not significant in pregnancy weeks 20 (P = 0·127, η 2 = 0·003) and 30 (P = 0·333, η 2 = 0·001). The effect of toxo-RhD interaction was significant in pregnancy weeks 16 (P < 0·001, η 2 = 0·019), 20 (P = 0·010, η 2 = 0·007) and 30 (P = 0·049, η 2 = 0·004). The continuous predictor maternal age was significant in pregnancy weeks 16 and 20 (P < 0·001, η 2 = 0·017 and P < 0·001, η 2 = 0·014, respectively) and was nearly significant in pregnancy week 30 (P = 0·068, η 2 = 0·004). The exact pregnancy length was not estimated with ultrasonography at the last examination at around pregnancy week 36. Therefore, the influence of toxoRhD interaction on maternal weight gain in pregnancy week 36 in the set of 958 mothers was analysed by GLM in the model with the binary variables toxo and RhD and continuous variable maternal age. The effect of toxo was significant (P = 0·037, η 2 = 0·005) while the effect of RhD was not significant (P = 0·321, η 2 = 0·001) but the effect of toxo-RhD interaction was significant again (P = 0·016, η 2 = 0·006). The effect of the continuous predictor maternal age was not significant (P = 0·657, η 2 < 0·001). At all 4 timepoints, i.e. in pregnancy weeks 16, 20, 30 and about 36, maternal weight gain was the highest in Toxoplasma-infected and RhD-negative mothers and this effect was always significant. The difference of about 1600 g observed in pregnancy week 16 (4·12 kg in 25 RhD-negative, Toxoplasma-infected vs. 2·44 kg in 127 RhD-negative, Toxoplasma-free, 2·65 kg in 590 RhD-positive, Toxoplasma-free and 2·35 kg in 158 RhD-positive, Toxoplasma-infected mothers) remained approximately constant until the end of pregnancy (Fig. 2) .
The effect of toxoplasmosis on maternal weight gain was analysed separately for RhD-negative and RhD-positive women. The effect of toxo on maternal weight gain in pregnancy weeks 16, 20, 30 and 36 was significant in RhD-negative mothers (week 16: P = 0·001, η 2 = 0·073; week 20: P = 0·012, η 2 = 0·040; week 30: P = 0·027, η 2 = 0·031; week 36: P = 0·009, η 2 = 0·041) but was not significant in RhDpositive mothers (week 16: P = 0·083, η 2 = 0·004; week 20: P = 0·420, η 2 = 0·001; week 30: P = 0·826, η 2 < 0·001; week 36: P = 0·654, η 2 < 0·001). The effect of maternal age on maternal weight gain was observed in both RhD-negative women (week 16: P = 0·011, η 2 = 0·043; week 20: P = 0·096, η 2 = 0·018; week 30: P = 0·484, η 2 = 0·003; week 36: P = 0·558, η 2 = 0·002) and RhD-positive women (week 16: P = 0·003, η 2 = 0·012; week 20: P = 0·001, η 2 = 0·014; week 30: P = 0·091, η 2 = 0·004; week 36: P = 0·496, η 2 = 0·001). As toxoplasmosis is known to influence the secondary sex ratio (Kaňková et al. 2007a, b) and the effect of toxo-RhD interaction on maternal weight gain could be just a side-effect of different developmental rates of male and female fetuses, we analysed the maternal weight gain separately for mothers who gave birth to male and female newborns. The effect of toxo-RhD interaction on maternal weight gain was significant in pregnancy week 16 (P < 0·001, η 2 = 0·026), nearly significant in pregnancy weeks 20 (P = 0·075, η 2 = 0·006) and 36 (P = 0·082, η 2 = 0·006) but was not significant in pregnancy week 30 (P = 0·182, η 2 = 0·003) in mothers of male newborns. In mothers of female newborns, the effect of toxoRhD interaction on maternal weight gain was significant in pregnancy week 16 (P = 0·040, η 2 = 0·011), nearly significant in pregnancy week 20 (P = 0·067, η 2 = 0·008) but was not significant in pregnancy weeks 30 (P = 0·121, η 2 = 0·006) and 36 (P = 0·100, η 2 = 0·007).
To investigate whether toxoplasmosis also influences fetal growth, we analysed the effect of toxoRhD interaction on fetal bioparameters measured by ultrasound at pregnancy weeks 20 and 30. Two continuous variables maternal age and pregnancy length estimated from the date of the last menstrual period were included into the models (and appeared significant in all models). As the sex of newborns is known to influence the fetal bioparameters, birth weight and birth length, we analysed this model with a third fixed factor, sex of newborn. Toxo-RhD interaction had no effect on fetal bioparameters at pregnancy weeks 20 and 30 in the whole study set (Table 1) . Similarly, toxo, RhD and toxo-RhD interaction had no effect on birth length and birth weight, results not shown.
D I S C U S S I O N
The present study showed that RhD-negative women with latent toxoplasmosis gained more weight during pregnancy than RhD-negative, Toxoplasma-free women or RhD-positive women. The difference was greatest in early pregnancy. In week 16, the mean maternal weight gain in 25 Rh-negative Toxoplasmainfected women was 4·12 kg compared to 2·50 kg in the other study groups. We also confirmed the earlier observation that Toxoplasma-infected women had higher weight before pregnancy than Toxoplasmafree women. The difference in maternal weight gain was not a side effect of higher sex ratio in Toxoplasma-infected mothers or differences in male and female fetal growth, as the same difference was observed in analyses performed separately for women with male and female children. Toxoplasmosis (and RhD) had no detectable effect on fetal growth or birth length and birth weight. Therefore, the higher pregnancy weight gain in Toxoplasma-infected RhD-negative mothers was probably due to higher weight of maternal tissues or higher volume of anmniotic fluid and placental tissues. To answer this important question, further data on maternal post-delivery weight would be needed.
Toxoplasma-free and Toxoplasma-infected women differ in several personality traits including Cattell's superego strength. Therefore, they could also differ systematically in time and regularity of visiting their gynecologist during pregnancy. This could systematically influence the observed pregnancy weight gain. To minimize this source of systematic error, we included length of pregnancy at the pre-natal visit into our statistical models. Theoretically, the length of pregnancy estimated from the first fetal ultrasound (performed usually at pregnancy weeks 8-12) could be systematically underestimated in Toxoplasmainfected women who showa lowerembryonic developmental rate than Toxoplasma-free mothers (Kaňková and Flegr, 2007) . Therefore, we also analysed the models either without the covariate length of pregnancy or with the length of pregnancy estimated from the date of the last menstrual period. All 3 categories of models provided approximately the same results (results not shown), which indicated that possibly underestimated length of pregnancy in Toxoplasmainfected women was not responsible for observed phenomena.
We confirmed the earlier observation of Abrams et al. (1995) that pregnancy weight gain is positively related to maternal age. Our data showed that both RhD-negative and RhD-positive women accounted for this phenomenon. This suggests that RhD 
positivity probably protects against the effect of toxoplasmosis but not against the effect of age. It must be remembered, however, that the reported protective effects of RhD-positivity against Toxoplasmainduced decrease of psychomotor performance were only transient in RhD-positive homozygotes (Novotná et al. 2008) . While the presence of a population of RhD-positive homozygotes can only partly mask the protective effects of RhD-positivity against latent toxoplasmosis-associated effects, it is probably much more difficult to demonstrate such protective effects of RhD-positivity against age-associated affects on the population containing RhD-positive homozygotes as the old RhD-positive homozygotes are expected to lack any protection. Monitoring the gestational weight gain is important for epidemiological and public health purposes. This indicator is correlated with infant growth (Abrams and Selvin, 1995) and may be related to maternal outcomes such as reproductive health and chronic disease risk (Strauss and Dietz, 1999) . Prospective studies identified gestational weight gain as a predictor of both infant birth weight (Abrams et al. 1995; Scholl et al. 1995; Hickey et al. 1996) and pre-term delivery (Schieve et al. 2000) . Excessive gestational weight gain is associated with increased risk of post-partum weight retention (Scholl et al. 1995; Olson et al. 2003) and increased risk of caesarean section (Johnson et al. 1992; Scholl et al. 1995) . Our data showed that RhD-negative women with latent toxoplasmosis gained weight more rapidly during the first trimester of pregnancy. A similar effect has already been found in smokers (Abrams et al. 1995) . Gestational weight gain during the first trimester is also positively associated with maternal age and with hypertension (Abrams et al. 1995; Dawes and Grudzinskas, 1991) . It can be generalized that excessive weight gain in the first trimester of pregnancy usually implies a negative effect of some internal (genetic or epigenetic) or external (environmental) factor(s).
The major limitation of the present study is the absence of data on RHD genotype of the pregnant women. A published case-control study performed on a large sample of blood donors showed that RhDpositive heterozygotes are resistant to the pathological effect of toxoplasmosis while RhD-positive homozygotes are resistant only temporarily -their psychomotor performance decreases with length of the infection (Novotná et al. 2008) . The psychomotor performance of RhD-negative homozygotes decreases immediately after the infection (Novotná et al. 2008) . Our population of RhD-positive pregnant women contains both RhD-positive heterozygotes and RhD-positive homozygotes (some of them with a relatively low concentration of antiToxoplasma antibodies and therefore relatively old infection). The contamination of the protected population of RhD-positive heterozygotes by an unknown number of possibly non-protected RhDpositive homozygotes probably decreased the power of our tests and the strength of the observed effects.
Three recent studies (Novotná et al. 2008; Flegr et al. 2008a Flegr et al. , 2009 ) have reported a protective effect of the RhD-positive phenotype, especially RhD heterozygosity, against the negative effect of latent toxoplasmosis on psychomotor performance of infected subjects. The present results indicate that the RhD-positive phenotype could also protect against a broader spectrum of detrimental effects of latent toxoplasmosis. The physiological role of RhD protein (an ion pump of uncertain specificity present in the red blood cell membrane) is unknown. Similarly, the mechanism of effects of toxoplasmosis on psychomotor performance (Havlíček et al. 2001) , length of pregnancy (Kaňková and Flegr, 2007) or sex ratio (Kaňková et al. 2007a, b) is unclear. Until the role of RhD protein in human physiology and the mechanism of toxoplasmosis-associated changes are elucidated, any speculation about the physiological and molecular mechanisms of the protective effect of RhD-positivity in pregnant Toxoplasma-infected women would be rather premature.
